161 related articles for article (PubMed ID: 37076494)
1. Co-administration with A1M does not influence apoptotic response of
Rassol N; Andersson C; Pettersson D; Al-Awar A; Shubbar E; Kovács A; Åkerström B; Gram M; Helou K; Forssell-Aronsson E
Sci Rep; 2023 Apr; 13(1):6417. PubMed ID: 37076494
[TBL] [Abstract][Full Text] [Related]
2. Hedgehog inhibitor sonidegib potentiates
Spetz J; Langen B; Rudqvist N; Parris TZ; Helou K; Nilsson O; Forssell-Aronsson E
BMC Cancer; 2017 Aug; 17(1):528. PubMed ID: 28789624
[TBL] [Abstract][Full Text] [Related]
3. Recombinant α
Andersson CK; Shubbar E; Schüler E; Åkerström B; Gram M; Forssell-Aronsson EB
J Nucl Med; 2019 Nov; 60(11):1600-1604. PubMed ID: 30926650
[TBL] [Abstract][Full Text] [Related]
4. Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after
Spetz J; Rudqvist N; Langen B; Parris TZ; Dalmo J; Schüler E; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
Nucl Med Biol; 2018 May; 60():11-18. PubMed ID: 29502008
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional effects of
Spetz J; Langen B; Rudqvist NP; Parris TZ; Shubbar E; Dalmo J; Wängberg B; Nilsson O; Helou K; Forssell-Aronsson E
EJNMMI Res; 2019 Mar; 9(1):28. PubMed ID: 30895393
[TBL] [Abstract][Full Text] [Related]
6. Priming increases the anti-tumor effect and therapeutic window of
Dalmo J; Spetz J; Montelius M; Langen B; Arvidsson Y; Johansson H; Parris TZ; Helou K; Wängberg B; Nilsson O; Ljungberg M; Forssell-Aronsson E
EJNMMI Res; 2017 Dec; 7(1):6. PubMed ID: 28097640
[TBL] [Abstract][Full Text] [Related]
7. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1.
Swärd C; Bernhardt P; Johanson V; Schmitt A; Ahlman H; Stridsberg M; Forssell-Aronsson E; Nilsson O; Kölby L
Cancer Biother Radiopharm; 2008 Feb; 23(1):114-20. PubMed ID: 18298335
[TBL] [Abstract][Full Text] [Related]
8. Hyperfractionated Treatment with
Elvborn M; Shubbar E; Forssell-Aronsson E
Cancers (Basel); 2022 Jan; 14(1):. PubMed ID: 35008397
[TBL] [Abstract][Full Text] [Related]
9. Protection of Kidney Function with Human Antioxidation Protein α
Kristiansson A; Ahlstedt J; Holmqvist B; Brinte A; Tran TA; Forssell-Aronsson E; Strand SE; Gram M; Åkerström B
Antioxid Redox Signal; 2019 May; 30(14):1746-1759. PubMed ID: 29943622
[TBL] [Abstract][Full Text] [Related]
10. Neuroblastoma xenograft models demonstrate the therapeutic potential of
Romiani A; Spetz J; Shubbar E; Lind DE; Hallberg B; Palmer RH; Forssell-Aronsson E
BMC Cancer; 2021 Aug; 21(1):950. PubMed ID: 34433438
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Therapeutic Response to Treatment with a 177Lu-Labeled Somatostatin Receptor Agonist and Antagonist in Preclinical Models.
Dalm SU; Nonnekens J; Doeswijk GN; de Blois E; van Gent DC; Konijnenberg MW; de Jong M
J Nucl Med; 2016 Feb; 57(2):260-5. PubMed ID: 26514177
[TBL] [Abstract][Full Text] [Related]
12. Peptide Receptor Radionuclide Therapy with
Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
[TBL] [Abstract][Full Text] [Related]
13. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
14.
Kristiansson A; Örbom A; Ahlstedt J; Karlsson H; Zedan W; Gram M; Åkerström B; Strand SE; Altai M; Strand J; Vilhelmsson Timmermand O
Biomolecules; 2021 Feb; 11(2):. PubMed ID: 33579037
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition.
Hofving T; Sandblom V; Arvidsson Y; Shubbar E; Altiparmak G; Swanpalmer J; Almobarak B; Elf AK; Johanson V; Elias E; Kristiansson E; Forssell-Aronsson E; Nilsson O
Endocr Relat Cancer; 2019 Apr; 26(4):437-449. PubMed ID: 30730850
[TBL] [Abstract][Full Text] [Related]
16. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors.
van Essen M; Krenning EP; Kam BL; de Herder WW; Feelders RA; Kwekkeboom DJ
J Nucl Med; 2010 Mar; 51(3):383-90. PubMed ID: 20150247
[TBL] [Abstract][Full Text] [Related]
18. Hematological toxicity of combined 177Lu-octreotate radiopeptide chemotherapy of gastroenteropancreatic neuroendocrine tumors in long-term follow-up.
Kesavan M; Claringbold PG; Turner JH
Neuroendocrinology; 2014; 99(2):108-17. PubMed ID: 24714208
[TBL] [Abstract][Full Text] [Related]
19. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
20. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]